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clones in peripheral blood could provide away to risk stratify
patients.
We collected endoscopic GI tract biopsy samples and
matched blood for fourteen patients undergoing myelo-
blative HCT with suspected GI GVHD within one day of
corticosteroid therapy. We also collected peripheral blood
approximately thirty days after biopsy. Seven of these
patients were negative for GVHD or had mild steroid
responsive GI GVHD and seven had severe steroid refractory
GI GVHD. We extracted genomic DNA and performed TCR
beta CDR3 repertoire sequencing at Stanford and with
Gigagen GigaMune Rep-Seq, using the Illumina next gener-
ation sequencing MiSeq and HiSeq platforms.
For each patient, between 1,000-5,000 unique T cell
sequences were identiﬁed in the endoscopic tissue. We
bracketed the most frequent clones in the GI tissue samples
by rank order cut-offs and a ﬂoating measure of skewness
and followed these clones in the blood. Both methods
showed that, on average, the GI identiﬁed clones increased in
frequency more in severe patients (51.2 +/- 39.2) when
compared to mild or negative patients (3.08 +/- 2.8; see
Figure 1). Additionally, patients in both groups who received
more steroids (mg/kg/day) showed a correlated reduction in
GI identiﬁed T cell expansion in the blood over time. These
results support the use of T cell repertoire sequencing and
associated approaches in human patients to both clarify the
pathophysiology of GVHD and may provide an independent
immune biomarker that could guide GVHD therapy.
Figure 1. GI identiﬁed TCR sequences become much more frequent in the
blood in an analysis of patients with severe steroid refractory GI GVHD as
compared to a patients with steroid responsive GVHD or without GVHD. (a)
Graphical depiction of the most frequent TCR sequence identiﬁed in the colon
and blood. Top panel shows the increasing frequency of the topped rank clone
(red), in contrast to the lower panel which shows the decreasing frequency of
the top ranked clone (green). (b) The mean fold change of TCR sequences
identiﬁed in the GI tract of patients tracked in the blood at day 30 to day of
diagnosis of 7 patients with severe GVHD and 7 patients with mild or no GVHD
(Wilcoxin Test, P < .002). GI sequences were identiﬁed as the top 100 by rank
order.
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Introduction: In allogeneic hematopoietic cell trans-
plantation (HCT), minor histocompatibility antigens (mHags)
are known to play an important role in generating immune
responses leading to graft-versus-leukaemia (GVL) effects
and graft-versus-host-disease (GVHD). mHags are results of
polymorphisms in the recipients genome, which cause
expression of peptides that can be recognised by donor T-
cells. Y-chromosomally encoded proteins constitute
a constant source of mHags relevant in allogeneic HCTs with
female donor and male recipient due to the disparities
between these and their homologue X-chromosomally
encoded counterparts.
Methods: A panel containing 8-11 mer peptides encom-
passing multiple putative and knownmHags encoded by the
Y-chromosome was designed using a bioinformatics
predictor of peptide-HLA binding, NetMHCpan. These
peptides were synthesized and used to screen for peptide-
speciﬁc T-cell responses in peripheral blood mononuclear
cells (PBMCs) obtained post-HCT from male recipients of
female donor grafts. Following in vitro stimulation, PBMCs
were analysed with an inteferon-g ELISpot assay. When
a response was found, the T-cells were further analyzed with
intracellular cytokine staining (ICS) and ﬂow cytometry to
determine whether it was a CD4- or a CD8-response. The
optimal epitope and the HLA-restriction was determined by
tetramer staining.
Results: In one male recipient of a female donor graft a T-cell
response was observed with ELISpot against the peptides
YFYYNAFHWAI and RESEEESVSL. ICS and ﬂow cytometry
revealed that both were CD8 responses. Both peptides were
earlier described mHags restricted by HLA-A*24:02 and HLA-
B60, respectively. Tetramer staining conﬁrmed that the
optimal epitopes were YYNAFHWAI and RESEEESVSL pre-
sented on HLA-A*24:02 and HLA-B*40:01 (a member of the
previously designated HLA-B60 speciﬁcity), respectively.
PBMCs obtained post HCT from ﬁve other male recipients of
female donor grafts have been analysed for T-cell responses
with ELISpot. Responses have been observed and further
analysis is ongoing.
Conclusion: Using a HLA-tetramer approach to identify the
optimal epitopes of two known mHags encoded by the Y-
chromosome as well as the presenting HLA restriction
elements at high resolution, we have demonstrated the
feasibility of a reverse immunology approach in mHag dis-
covery.
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Pulmonary function post allogeneic hematopoietic stem cell
transplant (HSCT) can be impaired by previous exposure to
chemotherapy, infection, or graft versus host disease
(GVHD). In this retrospective study, we analyzed 21 patients
with hematologic malignancies who are long term trans-
plant survivors with a median follow-up of 48 months who
had received a related (60%) or unrelated (40%) HSCT
conditionedwith a busulfan-based regimen. Of 21 patients, 7
are of Caucasian and 14 non-Caucasian ethnicity. All patients
had routine pulmonary function tests (PFTs) repeated within
two years from transplant and none had underlying lung
disease. To eliminate inter-lab variability, all PFTs were
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